文献速递心脑血管急症

急性主动脉综合征症状发作至D-二聚体检测的时间间隔不影响D-二聚体的筛查价值

D-dimer measurement is useful irrespective of time from the onset of acute aortic syndrome symptoms.
PubMed 文献 · Am J Emerg Med · 2023-06-07
一句话结论急性主动脉综合征患者D-二聚体在症状发作早期即升高,其筛查效用不受发病至检测时间间隔影响,而受AAS特征影响。

该研究回顾性分析2011至2021年本院连续诊断为急性主动脉综合征(AAS)的273例患者,按症状发作至D-二聚体检测时间间隔四分位分组(组1≤1h、组2 1-2h、组3 2-5h、组4>5h),比较各组D-二聚体水平及阳性率。结果显示各组D-二聚体阳性率(97%、96%、99%、99%,P=0.76)和年龄校正D-二聚体阳性率(96%、90%、96%、97%,P=0.32)均无显著差异。147例重复检测患者中9例初次或二次D-二聚体阴性,其中8例为血栓化假腔、1例为开放假腔但夹层长度短,所有9例D-二聚体最高仅1.4 μg/mL。结论认为D-二聚体在AAS早期即升高,其临床效用不受检测时间间隔影响,而受AAS特征影响。

要点

  • AAS患者D-二聚体在症状发作≤1h即多已升高,各组阳性率97%-99%(P=0.76),无需因发病时间短而等待复查。
  • 年龄校正D-二聚体阳性率各组为90%-97%(P=0.32),同样不受发病至检测时间间隔影响。
  • 重复检测中9例D-二聚体阴性者,8例为血栓化假腔、1例为开放假腔但夹层长度短,D-二聚体最高仅1.4 μg/mL。
  • D-二聚体筛查AAS的效用受AAS特征(如假腔血栓化、夹层长度短)影响,而非检测时机。

适用人群与场景

  • 2011至2021年于本院就诊并诊断为急性主动脉综合征(AAS)的连续患者273例。

诊断标准与关键阈值

  • D-二聚体阳性定义为D-二聚体≥0.5 μg/mL。
  • 年龄校正D-二聚体阳性定义为年龄校正D-二聚体≥[年龄(岁)×0.01] μg/mL(最低0.5 μg/mL)。

研究设计与关键结果

  • 回顾性分析273例AAS患者,按症状发作至D-二聚体检测时间间隔四分位分为4组:组1≤1h、组2 1-2h、组3 2-5h、组4>5h。
  • 各组D-二聚体阳性率分别为组1 97%、组2 96%、组3 99%、组4 99%,组间无显著差异(P=0.76)。
  • 各组年龄校正D-二聚体阳性率分别为组1 96%、组2 90%、组3 96%、组4 97%,组间无显著差异(P=0.32)。
  • 147例患者重复检测D-二聚体,其中9例初次或二次检测D-二聚体阴性;9例中8例AAS为血栓化假腔,1例为开放假腔但夹层长度短。
  • 9例D-二聚体阴性患者中D-二聚体水平持续低值,最高为1.4 μg/mL。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为D-二聚体在AAS早期即升高,其临床效用不受发病至检测时间间隔影响,而受AAS特征影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In acute aortic syndrome (AAS) screening, D-dimer is a well-established biomarker whose usefulness has been scarcely studied with respect to its measurement timing. We aimed to evaluate the effectiveness of D-dimer-based AAS screening focused on the time interval between AAS onset and D-dimer measurement.

METHODS: We retrospectively analyzed consecutive patients diagnosed with AAS who visited our hospital between 2011 and 2021. For the primary analysis, we divided patients according to the quartiles of the time interval between AAS symptom onset and D-dimer measurement. D-dimer level ≥ 0.5 μg/mL and age-adjusted D-dimer ≥ [age (years) × 0.01] μg/mL (minimum of 0.5 μg/mL) were defined as positive. The primary endpoint was the comparative ability of D-dimer to detect AAS within and between each time quartile. In an exploratory secondary analysis, we reported patient and AAS characteristics in the subgroup of patients who underwent repeat D-dimer measurement within 48 h of the first D-dimer measure.

RESULTS: The 273 AAS patients were divided into four groups based on quartiles of the time interval (Group 1, ≤1 h; Group 2, 1-2 h; Group 3, 2-5 h; and Group 4, >5 h). There were no significant differences in D-dimer levels or in the proportions with positive D-dimer (Group 1: 97%, Group 2: 96%, Group 3: 99%, Group 4: 99%; P = 0.76) or positive age-adjusted D-dimer (Group 1: 96%, Group 2: 90%, Group 3: 96%, Group 4: 97%; P = 0.32) between the groups. Of the 147 patients who had D-dimer re-measured, nine had negative D-dimer levels on either the primary or secondary measurement. Of these nine patients, eight had AAS with a thrombosed false lumen and one with a patent false lumen had a short length of dissection. In all nine patients, D-dimer levels remained low (maximum of 1.4 μg/mL).

CONCLUSION: D-dimer levels were elevated from the early stages of AAS. The clinical utility of D-dimer is not affected by the time interval from AAS onset to D-dimer measurement, but rather is influenced by AAS characteristics.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Otani T, Abe T, Ichiba T, et al. D-dimer measurement is useful irrespective of time from the onset of acute aortic syndrome symptoms. Am J Emerg Med. 2023. PMID: 37315439. doi:10.1016/j.ajem.2023.05.044

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。